Nova Mentis Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment

VANCOUVER, BC, Sept. 14, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or…

Nova Mentis Expands Psilocybin Research Program Targets Obesity and Diabetes

VANCOUVER, BC, Sept. 7, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the…

Nova Mentis Files Fragile X Orphan Drug Designation with European Medicines Agency

VANCOUVER, BC, Aug. 12, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the…

Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics

VANCOUVER, BC, July 29, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the…

Nova Mentis Appoints Dr. Stephen Glazer as Director and Chief Science Officer

VANCOUVER, BC, July 15, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the…

Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board

VANCOUVER, BC, June 23, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the…

Nova Mentis Launches Autism Clinical Study

VANCOUVER, BC, May 6, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the…

Nova Mentis Organizes Autism Data Bank in North America

VANCOUVER, BC, April 20, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the…

Nova Mentis Establishes Serotonin Research Centre

New Partnership with FourthWall Testing VANCOUVER, BC, March 31, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA)…

Nova Mentis Announces Promising Research Results

Psilocybin formulation Modulates Anxiety-Like Behaviour in Rat Autism Model VANCOUVER, BC, March 29, 2021 /CNW/ – Nova Mentis Life…

Nova Mentis Launches Autism Microbiome Study in the United States

VANCOUVER, BC, March 3, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the…

Nova Mentis Autism Clinical Study Approved by Institutional Review Board

VANCOUVER, BC, Feb. 25, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”),…